Impact of preanalytical delay on the performance of plasma Aβ42, Aβ42/40, p-tau217, and p-tau217/Aβ42 in detecting brain amyloidosis in the ALZAN cohort.

ABSTRACT:

Background

Alzheimer disease (AD), the leading cause of dementia, has increased interest in the development of blood-based biomarkers for early diagnosis and monitoring. The plasma amyloid beta (Aβ)42/Aβ40 ratio and phosphorylated tau (p-tau) isoforms closely align with cerebrospinal fluid and positron emission tomography markers. The recent approval of the plasma p-tau217/Aβ42 ratio marks a key step toward non-invasive diagnostics. However, known Aβ42's preanalytical and analytical challenges raise concerns about the reliability of this ratio in routine clinical practice.

Methods

Using the ALZAN prospective cohort of cognitively impaired individuals, we examined how delays between blood collection and laboratory processing affected the performance of plasma biomarkers in de

SUBMITTER: Delaby C 

PROVIDER: S-EPMC12574711 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature